株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

卵巣癌:パイプライン製品の分析

Ovarian Cancer - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 229719
出版日 ページ情報 英文 2027 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.80円で換算しております。
Back to Top
卵巣癌:パイプライン製品の分析 Ovarian Cancer - Pipeline Review, H1 2017
出版日: 2017年06月30日 ページ情報: 英文 2027 Pages
概要

卵巣癌の大多数は、卵巣の上皮(外膜)に発生します。卵巣癌の兆候や症状には、骨盤の不快感や痛み、消化不良、悪心、便秘といった排便サイクルの変化、食欲不振、腰痛などがあります。この疾患の素因には、加齢と家系が大きくかかわっています。

当レポートでは、卵巣癌治療薬におけるパイプライン製品の概要や治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

卵巣癌の概要

治療薬の開発

卵巣癌:企業で開発中の治療薬

卵巣癌:大学/機関で研究中の治療薬

卵巣癌:パイプライン製品の概況

卵巣癌:企業で開発中の製品

卵巣癌:大学/機関で研究中の製品

卵巣癌の治療薬開発に従事している企業

卵巣癌:治療薬の評価

薬剤プロファイル

卵巣癌:休止中のプロジェクト

卵巣癌:開発が中止された製品

卵巣癌:製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9474IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H1 2017, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 15, 135, 128, 7, 208, 21 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 14, 43 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Ovarian Cancer - Overview
  • Ovarian Cancer - Therapeutics Development
  • Ovarian Cancer - Therapeutics Assessment
  • Ovarian Cancer - Companies Involved in Therapeutics Development
  • Ovarian Cancer - Drug Profiles
  • Ovarian Cancer - Dormant Projects
  • Ovarian Cancer - Discontinued Products
  • Ovarian Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Ovarian Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..15), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..16), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..17), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..18), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..15), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..16), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..17), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..18), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..19), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..20), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..21), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..22), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..23), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..24), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..25), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..26), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..27), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..28), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..10), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..11), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..12), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..11), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..12), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Ovarian Cancer - Pipeline by 3-V Biosciences Inc, H1 2017
  • Ovarian Cancer - Pipeline by 4SC AG, H1 2017
  • Ovarian Cancer - Pipeline by AB Science SA, H1 2017
  • Ovarian Cancer - Pipeline by AbbVie Inc, H1 2017
  • Ovarian Cancer - Pipeline by AbGenomics International Inc, H1 2017
  • Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
  • Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2017
  • Ovarian Cancer - Pipeline by Aduro BioTech Inc, H1 2017
  • Ovarian Cancer - Pipeline by Advanced Accelerator Applications SA, H1 2017
  • Ovarian Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H1 2017
  • Ovarian Cancer - Pipeline by Advantagene Inc, H1 2017
  • Ovarian Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Ovarian Cancer - Pipeline by Aeterna Zentaris Inc, H1 2017
  • Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Alkermes Plc, H1 2017
  • Ovarian Cancer - Pipeline by Almac Discovery Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Alpha Cancer Technologies Inc, H1 2017
  • Ovarian Cancer - Pipeline by Alteogen Inc, H1 2017
  • Ovarian Cancer - Pipeline by Altor BioScience Corp, H1 2017
  • Ovarian Cancer - Pipeline by Ambrx Inc, H1 2017
  • Ovarian Cancer - Pipeline by Amgen Inc, H1 2017
  • Ovarian Cancer - Pipeline by Anavex Life Sciences Corp, H1 2017
  • Ovarian Cancer - Pipeline by ANP Technologies Inc, H1 2017
  • Ovarian Cancer - Pipeline by AntiCancer Inc, H1 2017
  • Ovarian Cancer - Pipeline by Antigen Express Inc, H1 2017
  • Ovarian Cancer - Pipeline by Antoxis Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Aphios Corp, H1 2017
  • Ovarian Cancer - Pipeline by Aposense Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Aprea AB, H1 2017
  • Ovarian Cancer - Pipeline by arGEN-X BV, H1 2017
  • Ovarian Cancer - Pipeline by ARMO Biosciences Inc, H1 2017
  • Ovarian Cancer - Pipeline by Armour Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Arno Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by ArQule Inc, H1 2017
  • Ovarian Cancer - Pipeline by Array BioPharma Inc, H1 2017
  • Ovarian Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
  • Ovarian Cancer - Pipeline by Arvinas Inc, H1 2017
  • Ovarian Cancer - Pipeline by Astellas Pharma Inc, H1 2017
  • Ovarian Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by AstraZeneca Plc, H1 2017
  • Ovarian Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Athenex Inc, H1 2017
  • Ovarian Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Avipep Pty Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H1 2017
  • Ovarian Cancer - Pipeline by Bayer AG, H1 2017
  • Ovarian Cancer - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Bio-Path Holdings Inc, H1 2017
  • Ovarian Cancer - Pipeline by BioCancell Ltd, H1 2017
  • Ovarian Cancer - Pipeline by BioMoti Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Bionomics Ltd, H1 2017
  • Ovarian Cancer - Pipeline by BioNTech AG, H1 2017
  • Ovarian Cancer - Pipeline by Biotest AG, H1 2017
  • Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Ovarian Cancer - Pipeline by Boston Biomedical Inc, H1 2017
  • Ovarian Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Ovarian Cancer - Pipeline by Calithera Biosciences Inc, H1 2017
  • Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Cavion LLC, H1 2017
  • Ovarian Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Celgene Corp, H1 2017
  • Ovarian Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Cellectar Biosciences Inc, H1 2017
  • Ovarian Cancer - Pipeline by Celleron Therapeutics Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Cellular Biomedicine Group Inc, H1 2017
  • Ovarian Cancer - Pipeline by Celon Pharma SA, H1 2017
  • Ovarian Cancer - Pipeline by Celprogen Inc, H1 2017
  • Ovarian Cancer - Pipeline by Celsion Corp, H1 2017
  • Ovarian Cancer - Pipeline by Celyad SA, H1 2017
  • Ovarian Cancer - Pipeline by Ceronco Biosciences, H1 2017
  • Ovarian Cancer - Pipeline by CerRx Inc, H1 2017
  • Ovarian Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Cielo Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Clovis Oncology Inc, H1 2017
  • Ovarian Cancer - Pipeline by CohBar Inc, H1 2017
  • Ovarian Cancer - Pipeline by Coherus BioSciences Inc, H1 2017
  • Ovarian Cancer - Pipeline by Commence Bio Inc, H1 2017
  • Ovarian Cancer - Pipeline by Compliment Corp, H1 2017
  • Ovarian Cancer - Pipeline by Corcept Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017
  • Ovarian Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by CytomX Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Cytori Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by CytRx Corp, H1 2017
  • Ovarian Cancer - Pipeline by CZ BioMed Corp, H1 2017
  • Ovarian Cancer - Pipeline by DAE HWA Pharmaceutical Co Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
  • Ovarian Cancer - Pipeline by DEKK-TEC Inc, H1 2017
  • Ovarian Cancer - Pipeline by DelMar Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Ecrins Therapeutics SAS, H1 2017
  • Ovarian Cancer - Pipeline by Eisai Co Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Eli Lilly and Company, H1 2017
  • Ovarian Cancer - Pipeline by Endocyte Inc, H1 2017
  • Ovarian Cancer - Pipeline by EntreChem SL, H1 2017
  • Ovarian Cancer - Pipeline by Epigen Biosciences Inc, H1 2017
  • Ovarian Cancer - Pipeline by EpiThany Inc, H1 2017
  • Ovarian Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Exelixis Inc, H1 2017
  • Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Faron Pharmaceuticals Oy, H1 2017
  • Ovarian Cancer - Pipeline by Fate Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Forty Seven Inc, H1 2017
  • Ovarian Cancer - Pipeline by Fujifilm Corp, H1 2017
  • Ovarian Cancer - Pipeline by Galena Biopharma Inc, H1 2017
  • Ovarian Cancer - Pipeline by GamaMabs Pharma SA, H1 2017
  • Ovarian Cancer - Pipeline by Gene Techno Science Co Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Genelux Corp, H1 2017
  • Ovarian Cancer - Pipeline by Genentech Inc, H1 2017
  • Ovarian Cancer - Pipeline by Genisphere LLC, H1 2017
  • Ovarian Cancer - Pipeline by Genmab A/S, H1 2017
  • Ovarian Cancer - Pipeline by Genor BioPharma Co Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Gilead Sciences Inc, H1 2017
  • Ovarian Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Ovarian Cancer - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
  • Ovarian Cancer - Pipeline by GlycoNex Inc, H1 2017
  • Ovarian Cancer - Pipeline by Glycotope GmbH, H1 2017
  • Ovarian Cancer - Pipeline by GP Pharm SA, H1 2017
  • Ovarian Cancer - Pipeline by Gradalis Inc, H1 2017
  • Ovarian Cancer - Pipeline by GW Pharmaceuticals Plc, H1 2017
  • Ovarian Cancer - Pipeline by Halozyme Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Hemispherx Biopharma Inc, H1 2017
  • Ovarian Cancer - Pipeline by Horizon Pharma Plc, H1 2017
  • Ovarian Cancer - Pipeline by Ideaya Biosciences Inc, H1 2017
  • Ovarian Cancer - Pipeline by Ignyta Inc, H1 2017
  • Ovarian Cancer - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017
  • Ovarian Cancer - Pipeline by IMMD Inc, H1 2017
  • Ovarian Cancer - Pipeline by Immune Design Corp, H1 2017
  • Ovarian Cancer - Pipeline by Immune Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Immune Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Immunocore Ltd, H1 2017
  • Ovarian Cancer - Pipeline by ImmunoGen Inc, H1 2017
  • Ovarian Cancer - Pipeline by Immunomedics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Immunovaccine Inc, H1 2017
  • Ovarian Cancer - Pipeline by IMPACT Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Incyte Corp, H1 2017
  • Ovarian Cancer - Pipeline by Innate Immunotherapeutics Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Innate Pharma SA, H1 2017
  • Ovarian Cancer - Pipeline by Innovation Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Insys Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Inventiva, H1 2017
  • Ovarian Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Johnson & Johnson, H1 2017
  • Ovarian Cancer - Pipeline by Juno Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Komipharm International Co Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
  • Ovarian Cancer - Pipeline by La Jolla Pharmaceutical Company, H1 2017
  • Ovarian Cancer - Pipeline by Laboratoire HRA Pharma, H1 2017
  • Ovarian Cancer - Pipeline by Lantern Pharma Inc, H1 2017
  • Ovarian Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by LegoChem Biosciences Inc, H1 2017
  • Ovarian Cancer - Pipeline by Lidds AB, H1 2017
  • Ovarian Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017
  • Ovarian Cancer - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
  • Ovarian Cancer - Pipeline by Loxo Oncology Inc, H1 2017
  • Ovarian Cancer - Pipeline by Lymphocyte Activation Technologies SA, H1 2017
  • Ovarian Cancer - Pipeline by Mabion SA, H1 2017
  • Ovarian Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H1 2017
  • Ovarian Cancer - Pipeline by MacroGenics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Mateon Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by MaxiVAX SA, H1 2017
  • Ovarian Cancer - Pipeline by Mebiopharm Co Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Medestea Research & Production SpA, H1 2017
  • Ovarian Cancer - Pipeline by MediaPharma Srl, H1 2017
  • Ovarian Cancer - Pipeline by MedImmune LLC, H1 2017
  • Ovarian Cancer - Pipeline by Medivir AB, H1 2017
  • Ovarian Cancer - Pipeline by Merck & Co Inc, H1 2017
  • Ovarian Cancer - Pipeline by Merck KGaA, H1 2017
  • Ovarian Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Mersana Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Merus NV, H1 2017
  • Ovarian Cancer - Pipeline by Microlin Bio Inc, H1 2017
  • Ovarian Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Minerva Biotechnologies Corp, H1 2017
  • Ovarian Cancer - Pipeline by Moleculin Biotech Inc, H1 2017
  • Ovarian Cancer - Pipeline by MolMed SpA, H1 2017
  • Ovarian Cancer - Pipeline by Monopar Therapeutics LLC, H1 2017
  • Ovarian Cancer - Pipeline by Morphotek Inc, H1 2017
  • Ovarian Cancer - Pipeline by Mycenax Biotech Inc, H1 2017
  • Ovarian Cancer - Pipeline by NantKwest Inc, H1 2017
  • Ovarian Cancer - Pipeline by Natco Pharma Ltd, H1 2017
  • Ovarian Cancer - Pipeline by NBE-Therapeutics AG, H1 2017
  • Ovarian Cancer - Pipeline by Nektar Therapeutics, H1 2017
  • Ovarian Cancer - Pipeline by Neovacs SA, H1 2017
  • Ovarian Cancer - Pipeline by Nerviano Medical Sciences Srl, H1 2017
  • Ovarian Cancer - Pipeline by Neurimmune Holding AG, H1 2017
  • Ovarian Cancer - Pipeline by NewLink Genetics Corp, H1 2017
  • Ovarian Cancer - Pipeline by Northwest Biotherapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Novartis AG, H1 2017
  • Ovarian Cancer - Pipeline by NovaTarg Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Noviga Research AB, H1 2017
  • Ovarian Cancer - Pipeline by Novogen Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Noxopharm Ltd, H1 2017
  • Ovarian Cancer - Pipeline by NuCana BioMed Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2017
  • Ovarian Cancer - Pipeline by OBI Pharma Inc, H1 2017
  • Ovarian Cancer - Pipeline by Omeros Corp, H1 2017
  • Ovarian Cancer - Pipeline by Omnitura Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by OncBioMune Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Oncobiologics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Oncodesign SA, H1 2017
  • Ovarian Cancer - Pipeline by Oncolix Inc, H1 2017
  • Ovarian Cancer - Pipeline by Oncolytics Biotech Inc, H1 2017
  • Ovarian Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by OncoTartis Inc, H1 2017
  • Ovarian Cancer - Pipeline by OncoTherapy Science Inc, H1 2017
  • Ovarian Cancer - Pipeline by Oncternal Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Opsona Therapeutics Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Optimum Therapeutics LLC, H1 2017
  • Ovarian Cancer - Pipeline by ORCA Therapeutics BV, H1 2017
  • Ovarian Cancer - Pipeline by OSE Immunotherapeutics, H1 2017
  • Ovarian Cancer - Pipeline by Oxford BioMedica Plc, H1 2017
  • Ovarian Cancer - Pipeline by OXIS International Inc, H1 2017
  • Ovarian Cancer - Pipeline by Pangaea Biotech SL, H1 2017
  • Ovarian Cancer - Pipeline by Patrys Ltd, H1 2017
  • Ovarian Cancer - Pipeline by PDS Biotechnology Corp, H1 2017
  • Ovarian Cancer - Pipeline by PEP-Therapy SAS, H1 2017
  • Ovarian Cancer - Pipeline by Pfizer Inc, H1 2017
  • Ovarian Cancer - Pipeline by Pharma Mar SA, H1 2017
  • Ovarian Cancer - Pipeline by PharmAust Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Pharmicell Co Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Plexxikon Inc, H1 2017
  • Ovarian Cancer - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Precision Biologics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Prima BioMed Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Probility Media Corp, H1 2017
  • Ovarian Cancer - Pipeline by Propanac Biopharma Inc, H1 2017
  • Ovarian Cancer - Pipeline by PsiOxus Therapeutics Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Puma Biotechnology Inc, H1 2017
  • Ovarian Cancer - Pipeline by Quintessence Biosciences Inc, H1 2017
  • Ovarian Cancer - Pipeline by Radius Health Inc, H1 2017
  • Ovarian Cancer - Pipeline by Recepta Biopharma SA, H1 2017
  • Ovarian Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Rgenix Inc, H1 2017
  • Ovarian Cancer - Pipeline by Richter Gedeon Nyrt, H1 2017
  • Ovarian Cancer - Pipeline by Rosetta Genomics Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Rubicon Biotechnology Inc, H1 2017
  • Ovarian Cancer - Pipeline by RXi Pharmaceuticals Corp, H1 2017
  • Ovarian Cancer - Pipeline by Sanofi, H1 2017
  • Ovarian Cancer - Pipeline by Sanofi Pasteur SA, H1 2017
  • Ovarian Cancer - Pipeline by SATT North SAS, H1 2017
  • Ovarian Cancer - Pipeline by Selecta Biosciences Inc, H1 2017
  • Ovarian Cancer - Pipeline by Senhwa Biosciences Inc, H1 2017
  • Ovarian Cancer - Pipeline by Sequoia Sciences Inc, H1 2017
  • Ovarian Cancer - Pipeline by Siamab Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Sierra Oncology Inc, H1 2017
  • Ovarian Cancer - Pipeline by Sigma-Tau SpA, H1 2017
  • Ovarian Cancer - Pipeline by Sillajen Biotherapeutics, H1 2017
  • Ovarian Cancer - Pipeline by Soricimed Biopharma Inc, H1 2017
  • Ovarian Cancer - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Ovarian Cancer - Pipeline by Sotio AS, H1 2017
  • Ovarian Cancer - Pipeline by Starpharma Holdings Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Supratek Pharma Inc, H1 2017
  • Ovarian Cancer - Pipeline by Susavion Biosciences Inc, H1 2017
  • Ovarian Cancer - Pipeline by Symic Biomedical Inc, H1 2017
  • Ovarian Cancer - Pipeline by Syndax Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Syros Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Tactiva Therapeutics LLC, H1 2017
  • Ovarian Cancer - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Ovarian Cancer - Pipeline by Takis Srl, H1 2017
  • Ovarian Cancer - Pipeline by TapImmune Inc, H1 2017
  • Ovarian Cancer - Pipeline by Targovax ASA, H1 2017
  • Ovarian Cancer - Pipeline by Tesaro Inc, H1 2017
  • Ovarian Cancer - Pipeline by The Female Health Company, H1 2017
  • Ovarian Cancer - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Transgene SA, H1 2017
  • Ovarian Cancer - Pipeline by TVAX Biomedical Inc, H1 2017
  • Ovarian Cancer - Pipeline by Tyrogenex Inc, H1 2017
  • Ovarian Cancer - Pipeline by ValiRx Plc, H1 2017
  • Ovarian Cancer - Pipeline by Vascular Biogenics Ltd, H1 2017
  • Ovarian Cancer - Pipeline by VentiRx Pharmaceuticals Inc, H1 2017
  • Ovarian Cancer - Pipeline by Verastem Inc, H1 2017
  • Ovarian Cancer - Pipeline by VG Life Sciences Inc, H1 2017
  • Ovarian Cancer - Pipeline by ViiV Healthcare Ltd, H1 2017
  • Ovarian Cancer - Pipeline by ViraTherapeutics GmbH, H1 2017
  • Ovarian Cancer - Pipeline by Zymeworks Inc, H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..9), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..10), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..11), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..12), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..13), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..14), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..15), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..16), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..17), H1 2017
  • Ovarian Cancer - Dormant Projects, H1 2017 (Contd..18), H1 2017
  • Ovarian Cancer - Discontinued Products, H1 2017
  • Ovarian Cancer - Discontinued Products, H1 2017 (Contd..1), H1 2017
  • Ovarian Cancer - Discontinued Products, H1 2017 (Contd..2), H1 2017
  • Ovarian Cancer - Discontinued Products, H1 2017 (Contd..3), H1 2017

List of Figures

  • Number of Products under Development for Ovarian Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top